
COA: BST-CarGel is an effective adjunct to microfracture for articular cartilage lesions

COA: BST-CarGel is an effective adjunct to microfracture for articular cartilage lesions
An International Randomized Clinical Trial Evaluating Bst-Cargel, A Novel Scaffold For Cartilage Repair, Demonstrates Superiority Of Repair When Compared With Microfracture Alone Treatment
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
CONFERENCE ACE REPORTS
This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.
Synopsis
80 patients with an articular cartilage lesion, located on their femoral condyle, were randomized to undergo microfracture surgery with or without receiving BST-CarGel, to assess the efficacy and safety of BST-CarGel. 12 month results demonstrated that there was significantly greater improvement in quality and quantity of cartilage repair tissue in the BST-CarGel group, in comparison to the microf...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!

Learn about our AI Driven
High Impact Search Feature

The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.